MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (pharmaceuticals)
- Indian Pharma
Indian Pharma Stocks 
Here are the latest stock price details of India's top Indian Pharma stocks. For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results.
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | MORE INFO |
|---|---|---|---|---|
| AARTI DRUGS | 561.75 0.61% | 561.10 0.29% | More Info
|
|
| AJANTA PHARMA | 1,074.40 5.47% | 1,075.95 5.43% | More Info
|
|
| ALEMBIC PHARMA | 618.15 0.60% | 620.60 0.49% | More Info
|
|
| BIOCON LTD | 629.40 3.22% | 629.65 3.12% | More Info
|
|
| CADILA HEALTHCARE | 346.05 1.47% | 345.65 1.54% | More Info
|
|
| CIPLA | 519.75 1.32% | 518.70 1.20% | More Info
|
|
| DIVIS LABORATORIES | 1,477.65 0.38% | 1,478.05 0.37% | More Info
|
|
| GLENMARK PHARMA | 664.95 4.59% | 665.00 4.72% | More Info
|
|
| INDOCO REMEDIES | 219.10 0.32% | 219.55 0.69% | More Info
|
|
| IPCA LABS | 779.25 -2.15% | 782.85 -1.87% | More Info
|
|
| J.B.CHEMICALS | 294.25 -1.64% | 293.55 -1.79% | More Info
|
|
| LUPIN LTD | 835.35 2.49% | 835.00 2.74% | More Info
|
|
| NATCO PHARMA | 699.50 1.22% | 701.90 1.04% | More Info
|
|
| NIFTY 50 | Not Listed | 10,549.15 0.58% | More Info
|
|
| ORCHID PHARMA LTD | 5.00 0.40% | 18.90 -2.83% | More Info
|
|
| PANACEA BIOTECH | 156.45 1.00% | 155.45 0.39% | More Info
|
|
| PIRAMAL ENTERPRISES | 2,088.35 2.08% | 2,087.60 2.20% | More Info
|
|
| S&P BSE SENSEX | 35,150.01 0.54% | Not Listed | More Info
|
|
| STRIDES PHARMA SCIENCE | 458.40 6.42% | 459.30 6.59% | More Info
|
|
| SUN PHARMA | 421.80 5.75% | 422.30 5.84% | More Info
|
|
| TORRENT PHARMA | 1,688.35 -0.30% | 1,676.60 -0.67% | More Info
|
|
| WOCKHARDT LTD. | 493.90 2.71% | 493.50 2.80% | More Info
|
BSE prices: December 11, 2018 (Close) NSE prices: December 11, 2018 (Close)
Indian Pharma Stocks Update
The NIFTY PHARMA Index was at 8,765.3 (up 2.7%). The index is down 14.9% over the last 30 days. And over the last 1 year, it has lost 6.7%.
Within the Indian Pharma sector, the top gainers were STRIDES PHARMA SCIENCE (up 6.4%) and SUN PHARMA (up 5.8%). On the other hand, IPCA LABS (down 2.2%) and J.B.CHEMICALS (down 1.6%) were among the top losers.
Meanwhile, the benchmark NIFTY 50 was at 10,549.2 (up 0.6%).
|
| |
Today's Market
Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)
After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.
Related Views on News
AJANTA PHARMA Surges by 6%; BSE HEALTHCARE Index Up 2.0% (Market Updates)
Dec 11, 2018 | Updated on Dec 11, 2018AJANTA PHARMA share price has surged by 6% and its current market price is Rs 1,077. The BSE HEALTHCARE is up by 2.0%. The top gainers in the BSE HEALTHCARE Index are AJANTA PHARMA (up 5.6%) and SUN PHARMA (up 5.5%). The top losers are DR. LAL PATHLABS LTD (down 0.3%) and THYROCARE TECHNOLOGIES (down 0.4%).
SUN PHARMA Surges by 6%; BSE HEALTHCARE Index Up 2.0% (Market Updates)
Dec 11, 2018 | Updated on Dec 11, 2018SUN PHARMA share price has surged by 6% and its current market price is Rs 422. The BSE HEALTHCARE is up by 2.0%. The top gainers in the BSE HEALTHCARE Index is SUN PHARMA (up 5.6%). The top losers are THYROCARE TECHNOLOGIES (down 0.1%) and APOLLO HOSPITALS (down 0.1%).
PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)
Nov 27, 2018 | Updated on Nov 27, 2018For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
More Views on NewsMost Popular
My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)
Nov 30, 2018Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.
4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)
Dec 3, 2018Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.
Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)
Nov 29, 2018Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?
Safety Beats Growth in 2018(Chart Of The Day)
Nov 30, 2018With the markets turning up, these are my top 7 stock picks.
Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)
Dec 5, 2018Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.
More|
| |
S&P BSE HEALTHCARE
Dec 11, 2018 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.